Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 7.5 vs ADDERALL 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary p H (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Amphetamine and dextroamphetamine are metabolized primarily in the liver via oxidative deamination and aromatic hydroxylation. The major metabolic pathway involves the enzyme CYP2D6, which converts amphetamine to 4-hydroxyamphetamine and norephedrine. Other minor pathways include N-dealkylation and deamination.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Approximately 20-25% bound to plasma proteins (primarily albumin).
Approximately 15–20% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution, with high concentrations in the brain and cerebrospinal fluid.
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Oral bioavailability is approximately 75-80% for immediate-release formulations, with no significant food effect. Extended-release capsules have similar bioavailability when taken intact.
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
e GFR 30-89 m L/min: Administer 50% of usual dose; e GFR <30 m L/min: Not recommended due to accumulation; Hemodialysis: Not recommended.
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
Child-Pugh Class A: No adjustment necessary; Child-Pugh Class B: Reduce dose by 50%; Child-Pugh Class C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
Children ≥3 years (ADHD): Immediate-release: Starting dose 2.5 mg once or twice daily, increase by 2.5-5 mg/day weekly to max 40 mg/day in divided doses; Extended-release: ≥6 years: Starting 10 mg once daily, increase by 5-10 mg weekly to max 30 mg/day. Weight <30 kg: Use lower end of dosing range.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg at weekly intervals; maximum 40 mg/day; monitor for cardiovascular effects, insomnia, and appetite suppression.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADDERALL, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious Cardiovascular Events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities.,Blood Pressure and Heart Rate Increases: Monitor heart rate and blood pressure; use caution in patients with hypertension or tachycardia.,Psychiatric Adverse Events: May exacerbate pre-existing psychosis, mania, or cause new psychotic/manic symptoms.,Seizures: May lower seizure threshold; use with caution in patients with a history of seizures.,Peripheral Vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin Syndrome: Risk when co-administered with serotonergic drugs.,Growth Suppression: Monitor growth in pediatric patients during treatment.,Abuse and Dependence: High potential; prescribe cautiously and monitor for misuse.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Hypersensitivity to amphetamines or any components of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Symptomatic cardiovascular disease,Moderate to severe hypertension,Advanced arteriosclerosis
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Take with or without food, but consistency is recommended to avoid fluctuating absorption. Avoid acidic foods or large amounts of vitamin C (e.g., citrus fruits, juices) within 1 hour of dosing, as they can decrease absorption. Avoid high-fat meals which can delay absorption. Grapefruit and grapefruit juice may increase amphetamine levels; limit or avoid.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/third trimester: Risk of preterm delivery, low birth weight, and neonatal withdrawal (e.g., irritability, poor feeding).
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
Amphetamines are excreted into breast milk. M/P ratio unknown. Potential for infant stimulation, insomnia, and growth suppression. Breastfeeding not recommended during therapy.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
Decreased plasma levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased, but risk-benefit must be evaluated. Use lowest effective dose with close monitoring.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
Adderall 7.5 mg is a combination of amphetamine salts (dextroamphetamine and levoamphetamine) in a 3:1 ratio. It is a CNS stimulant indicated for ADHD and narcolepsy. Monitor for cardiovascular effects (BP, HR) prior to and during therapy. Use with caution in patients with hypertension, tachyarrhythmias, or history of substance abuse. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May cause growth suppression in children; monitor height and weight. Abuse potential is high; prescribe the smallest effective dose and use tamper-resistant formulations when possible.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Take exactly as prescribed; do not take more or more often than directed.,Swallow tablets whole; do not crush, chew, or break them.,Avoid taking late in the day to prevent insomnia.,Do not stop abruptly; sudden discontinuation can cause severe fatigue and depression.,Notify your doctor of any history of heart problems, high blood pressure, seizures, or mental health conditions.,Report any chest pain, shortness of breath, fainting, or seizures immediately.,Avoid alcohol and marijuana; they can increase side effects.,Store at room temperature away from moisture and heat.,Keep out of reach of children; this medication has a high risk of overdose.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 7.5 vs ADDERALL 12.5, answered by our medical review team.
ADDERALL 7.5 is a CNS Stimulant that works by ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.. ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 7.5 and ADDERALL 12.5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 7.5 is: 5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.. The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 7.5 and ADDERALL 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 7.5 is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.